奥林匹斯之门 pp电子奥林匹斯之门
About Us
Corporate Profile
Management Team
Milestones
Awards
Our Vision
Affiliates
CTTQ Akesobio
Akeso Pharma
AD Pharmaceuticals
Contact Us
R&D and science
Technology Platform
Products Center
R&D and Manufacturing
Expanded Access Policy
Collaborations
Investor Relations
Financial Reports
Presentations
IR Monthly Reports
Announcements and Circulars
Corporate Governance
IR Calendar
IR Contact
Media
Career
Social Recruitment
Campus Recruitment
简
|
EN
|
2026-03-30
Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
2026-03-27
Akeso Reports Full-Year 2025 Financial Results
2026-03-24
Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
2026-03-10
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
2026-03-04
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
2026-03-02
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results
2026-02-11
Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications
2026-02-06
Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
2026-01-29
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
2026-01-19
Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis
2026-01-14
Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
2026-01-07
Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
1
2
3
4
5
6
7
8
9
»
